193 related articles for article (PubMed ID: 38307424)
1. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
[TBL] [Abstract][Full Text] [Related]
2. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
3. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
[TBL] [Abstract][Full Text] [Related]
4. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
5. A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.
Pilozzi A; Foster S; Mischoulon D; Fava M; Huang X
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569888
[TBL] [Abstract][Full Text] [Related]
6. Human behavioral pharmacology of psychedelics.
Strickland JC; Johnson MW
Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
[TBL] [Abstract][Full Text] [Related]
7. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
Sousa TR; Rema J; Machado S; Novais F
Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
[TBL] [Abstract][Full Text] [Related]
8. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
9. Dosing Psychedelics and MDMA.
Liechti ME; Holze F
Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
[TBL] [Abstract][Full Text] [Related]
10. Psychedelics in the Treatment of Headache and Chronic Pain Disorders.
Schindler EAD
Curr Top Behav Neurosci; 2022; 56():261-285. PubMed ID: 35546382
[TBL] [Abstract][Full Text] [Related]
11. The use of classic psychedelics among adults: a Danish online survey study.
Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions involving classic psychedelics: A systematic review.
Halman A; Kong G; Sarris J; Perkins D
J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
Holze F; Singh N; Liechti ME; D'Souza DC
Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
15. Psychedelics and Personality.
Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
[TBL] [Abstract][Full Text] [Related]
16. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
[TBL] [Abstract][Full Text] [Related]
17. The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.
Winkelman MJ; Szabo A; Frecska E
Eur Neuropsychopharmacol; 2023 Nov; 76():3-16. PubMed ID: 37451163
[TBL] [Abstract][Full Text] [Related]
18. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA
Addict Biol; 2022 Nov; 27(6):e13229. PubMed ID: 36301215
[TBL] [Abstract][Full Text] [Related]
19. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
Videira NB; Nair V; Paquet V; Calhoun D
J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119
[TBL] [Abstract][Full Text] [Related]
20. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; Uberti DL; Memo M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
